MHRA approves Lynavoy for itch in adults with PBC

The MHRA said on 1 May 2026 that it had approved linerixibat, which will be sold as Lynavoy, to treat itching in adults with primary biliary cholangitis, or PBC. That may sound like a small step if you do not know the condition, but for many patients itching is not a minor annoyance. It can shape sleep, concentration and everyday comfort. According to the MHRA, this approval gives adults with PBC another treatment option when itching is part of the illness. That matters because news about medicines can often feel full of technical language, and what patients usually want first is the plain-English version: what the drug is for, what the evidence showed, and what approval actually changes.

PBC is a long-term liver condition in which the small bile ducts in the liver become damaged. When that happens, bile acids can build up in the blood. The government announcement explains that this build-up is thought to be one reason some people with PBC develop persistent itching. If you are new to the term, it helps to separate the disease from one of its symptoms. Lynavoy is not being presented as a cure for PBC itself. It has been approved to help with the itching linked to the condition, which is an important distinction for patients trying to understand what this medicine can and cannot do.

The way the drug is given is fairly straightforward. The MHRA says linerixibat is an oral film-coated tablet, and the recommended dose is one tablet taken twice a day. In simple terms, this is a medicine you swallow rather than an injection or hospital infusion. The explanation from the MHRA is that linerixibat helps reduce the build-up of substances in the body, including bile acids, and that in turn can reduce itching. **What this means for patients:** the medicine is aimed at easing a symptom that can be exhausting and disruptive, especially when it affects sleep over long periods.

The evidence behind the decision comes from a global Phase 3 clinical trial called Glisten. In that study, 238 patients were randomly assigned to receive either linerixibat 40 mg twice a day or a placebo for 24 weeks. A placebo is a lookalike treatment with no active drug, used so researchers can make a fair comparison. According to the MHRA, the trial showed that linerixibat significantly reduced itching and also improved sleep disruption caused by itching. The main measurement, called the Monthly Itch Score, showed a statistically significant improvement in the group taking linerixibat compared with the placebo group. **Why Phase 3 matters:** this is the late-stage testing used to show whether a medicine works well enough, and safely enough, to be considered for wider use.

Approval does not mean the checking stops. Julian Beach, the MHRA's Interim Executive Director of Healthcare Quality and Access, said the decision provides a new treatment option for adults with PBC who experience itching, and added that the regulator will continue to monitor the medicine's safety and effectiveness as use becomes more widespread. That ongoing watch is a routine part of medicines regulation. The approval was granted to GlaxoSmithKline UK Limited and, according to the MHRA notes, the product went through the National Procedure. The regulator also said the Summary of Product Characteristics and the Patient Information Leaflet would be published on the MHRA products website within seven days of approval, giving clinicians and patients fuller detail on use and side effects.

For readers trying to work out what happens next, the practical point is this: approval opens the door, but it does not mean every patient will start the medicine immediately. Decisions about whether Lynavoy is suitable will still sit with clinicians and patients, using the published prescribing information and the person's own medical history. The MHRA also reminds patients to speak to a doctor, pharmacist or nurse if they think they are having a side effect, and to report suspected side effects through the Yellow Card scheme. That is one of the less visible parts of how medicine safety works in the UK. **What it means in everyday terms:** a drug can be approved because the benefits outweigh the risks, while doctors, patients and the regulator still keep watch as more people begin to use it.